{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:47:34Z","timestamp":1793173654088,"version":"4.5.0"},"reference-count":54,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"abstract":"<jats:sec><jats:title>CONTEXT:<\/jats:title><jats:p>As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Many medical treatments for ASDs have been proposed and studied, but there is currently no consensus regarding which interventions are most effective.<\/jats:p><\/jats:sec><jats:sec><jats:title>OBJECTIVE:<\/jats:title><jats:p>To systematically review evidence regarding medical treatments for children aged 12 years and younger with ASDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>We searched the Medline, PsycInfo, and ERIC (Education Resources Information Center) databases from 2000 to May 2010, regulatory data for approved medications, and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion\/exclusion criteria. Studies of secretin were not included in this review. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Evidence supports the benefit of risperidone and aripiprazole for challenging and repetitive behaviors in children with ASDs. Evidence also supports significant adverse effects of these medications. Insufficient strength of evidence is present to evaluate the benefits or adverse effects for any other medical treatments for ASDs, including serotonin-reuptake inhibitors and stimulant medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Although many children with ASDs are currently treated with medical interventions, strikingly little evidence exists to support benefit for most treatments. Risperidone and aripiprazole have shown benefit for challenging and repetitive behaviors, but associated adverse effects limit their use to patients with severe impairment or risk of injury.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2011-0427","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T02:50:04Z","timestamp":1301971804000},"page":"e1312-e1321","source":"Crossref","is-referenced-by-count":304,"title":["A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders"],"prefix":"10.1542","volume":"127","author":[{"given":"Melissa L.","family":"McPheeters","sequence":"first","affiliation":[{"name":"Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health; and"},{"name":"Department of Obstetrics and Gynecology, Vanderbilt University Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Warren","sequence":"additional","affiliation":[{"name":"Departments of Psychiatry and Pediatrics;"},{"name":"Vanderbilt Kennedy Center\/Treatment and Research Institute for Autism Spectrum Disorders;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nila","family":"Sathe","sequence":"additional","affiliation":[{"name":"Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Bruzek","sequence":"additional","affiliation":[{"name":"Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Krishnaswami","sequence":"additional","affiliation":[{"name":"Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca N.","family":"Jerome","sequence":"additional","affiliation":[{"name":"Eskind Biomedical Library and Department of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Veenstra-VanderWeele","sequence":"additional","affiliation":[{"name":"Vanderbilt Kennedy Center\/Treatment and Research Institute for Autism Spectrum Disorders;"},{"name":"Departments of Psychiatry, Pediatrics, and Pharmacology,"},{"name":"Center for Molecular Neuroscience; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2011,5,1]]},"reference":[{"key":"2021121006574858400_B1","unstructured":"Autism and Developmental Disabilities Monitoring Network. Prevalence of the Autism Spectrum Disorders (ASDs) in Multiple Areas of the United States, 2004 and 2006. Atlanta, GA: Centers for Disease Control and Prevention; 2009. Available at: www.cdc.gov\/ncbddd\/autism\/states\/ADDMCommunityReport2009.pdf. Accessed March 9, 2011"},{"key":"2021121006574858400_B2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","edition":"4th ed."},{"issue":"5","key":"2021121006574858400_B3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1542\/peds.2008-1606","article-title":"Clinical assessment and management of toddlers with suspected autism spectrum disorder: insights from studies of high-risk infants","volume":"123","author":"Zwaigenbaum","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"2021121006574858400_B4","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1542\/peds.2007-2362","article-title":"Management of children with autism spectrum disorders","volume":"120","author":"Myers","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"2021121006574858400_B5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3928\/00904481-20090101-08","article-title":"Management of autism spectrum disorders in primary care","volume":"38","author":"Myers","year":"2009","journal-title":"Pediatr Ann"},{"key":"2021121006574858400_B6","unstructured":"National Autism Center. National Standards Report. Randolph, MA: National Autism Center; 2009. Available at: www.nationalautismcenter.org\/pdf\/NACStandardsReport.pdf. Accessed March 9, 2011"},{"key":"2021121006574858400_B7","unstructured":"National Research Council, Committee on Educational Interventions for Children With Autism. Educating Children With Autism. Washington, DC; National Academies Press; 2001. Available at: http:\/\/books.nap.edu\/catalog.php?record_id=10017. Accessed March 9, 2011"},{"key":"2021121006574858400_B8","unstructured":"Warren\u2008Z, Veenstra-VanderWeele\u2008J, Stone\u2008W, Bruzek\u2008JL, Nahmias\u2008AS, Foss-Feig\u2008JH, et al. Therapies for Children With Autism Spectrum Disorders. Comparative Effectiveness Review 26. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract 290-02-HHSA-290-2007-10065-I.) AHRQ Publication 11-EHC035-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2007Available at: www.effectivehealthcare.ahrq.gov\/reports\/final.cfm. Accessed March 2011"},{"issue":"5","key":"2021121006574858400_B9","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2011-0428","article-title":"A systematic review of secretin for children with autism spectrum disorders","volume":"127","author":"Krishnaswami","year":"2011","journal-title":"Pediatrics"},{"issue":"3","key":"2021121006574858400_B10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1005592401947","article-title":"The Autism Diagnostic Observation Schedule-Generic: a standard measure of social and communication deficits associated with the spectrum of autism","volume":"30","author":"Lord","year":"2000","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"2021121006574858400_B11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF02172145","article-title":"Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"24","author":"Lord","year":"1994","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"2021121006574858400_B12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jclinepi.2009.03.009","article-title":"AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions\u2014Agency for Healthcare Research and Quality and the effective health-care program","volume":"63","author":"Owens","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2021121006574858400_B13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/cap.2007.0133","article-title":"Cognitive effects of risperidone in children with autism and irritable behavior","volume":"18","author":"Aman","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"2021121006574858400_B14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"2021121006574858400_B15","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2021121006574858400_B16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2021121006574858400_B17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","article-title":"Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data","volume":"161","author":"Martin","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2021121006574858400_B18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"2021121006574858400_B19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/00004583-200312000-00011","article-title":"Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials","volume":"42","author":"Arnold","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"2021121006574858400_B20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/01.chi.0000196423.80717.32","article-title":"Risperidone and adaptive behavior in children with autism","volume":"45","author":"Williams","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"2021121006574858400_B21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"2","key":"2021121006574858400_B22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"2021121006574858400_B23","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"issue":"6","key":"2021121006574858400_B24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study","volume":"21","author":"Nagaraj","year":"2006","journal-title":"J Child Neurol"},{"issue":"9","key":"2021121006574858400_B25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4088\/JCP.v64n0909","article-title":"A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone","volume":"64","author":"Masi","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"2021121006574858400_B26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"2021121006574858400_B27","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"2021121006574858400_B28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.2004.00546.x","article-title":"Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial","volume":"29","author":"Akhondzadeh","year":"2004","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"2021121006574858400_B29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/tpj.2009.63","article-title":"Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions","volume":"10","author":"Correia","year":"2010","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"2021121006574858400_B30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"2021121006574858400_B31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1469-8749.2002.tb00266.x","article-title":"Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement","volume":"44","author":"DeLong","year":"2002","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"2021121006574858400_B32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"2021121006574858400_B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aur.109","article-title":"A pharmacogenetic study of escitalopram in autism spectrum disorders","volume":"3","author":"Owley","year":"2010","journal-title":"Autism Res"},{"issue":"1\u20132","key":"2021121006574858400_B34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/cap.2006.16.187","article-title":"Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review","volume":"16","author":"Henry","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"2021121006574858400_B35","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity","volume":"62","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"2021121006574858400_B36","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","article-title":"Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures","volume":"61","author":"Posey","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2021121006574858400_B37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10803-008-0636-9","article-title":"Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity","volume":"39","author":"Jahromi","year":"2009","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"2021121006574858400_B38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/DBP.0b013e31815f24f7","article-title":"Stimulant medication treatment of target behaviors in children with autism: a population-based study","volume":"29","author":"Nickels","year":"2008","journal-title":"J Dev Behav Pediatr"},{"issue":"2","key":"2021121006574858400_B39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/1044546041649084","article-title":"Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases","volume":"14","author":"Posey","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"2021121006574858400_B40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/104454604773840481","article-title":"A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders","volume":"14","author":"Stigler","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"2021121006574858400_B41","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/01.chi.0000220854.79144.e7","article-title":"Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders","volume":"45","author":"Scahill","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"2021121006574858400_B42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02211843","article-title":"The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children","volume":"19","author":"Anderson","year":"1989","journal-title":"J Autism Dev Disord"},{"issue":"10","key":"2021121006574858400_B43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","article-title":"Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms","volume":"141","author":"Anderson","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2021121006574858400_B44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1089\/cap.2005.15.116","article-title":"Medication patterns in patients with autism: temporal, regional, and demographic influences","volume":"15","author":"Aman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"2021121006574858400_B45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1025883612879","article-title":"Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio","volume":"33","author":"Aman","year":"2003","journal-title":"J Autism Dev Disord"},{"issue":"9","key":"2021121006574858400_B46","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s10803-009-0750-3","article-title":"A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders","volume":"39","author":"Esbensen","year":"2009","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"2021121006574858400_B47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.biopsych.2006.05.007","article-title":"Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study","volume":"61","author":"Amminger","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"10","key":"2021121006574858400_B48","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121006574858400_B49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2431-9-21","article-title":"Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial","volume":"9","author":"Rossignol","year":"2009","journal-title":"BMC Pediatr"},{"issue":"7","key":"2021121006574858400_B50","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","article-title":"Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders","volume":"67","author":"Guastella","year":"2010","journal-title":"Biol Psychiatry"},{"issue":"1","key":"2021121006574858400_B51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-006-0518-9","article-title":"A retrospective study of memantine in children and adolescents with pervasive developmental disorders","volume":"191","author":"Erickson","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"issue":"26","key":"2021121006574858400_B52","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1056\/NEJMoa0804633","article-title":"Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety","volume":"359","author":"Walkup","year":"2008","journal-title":"N Engl J Med"},{"issue":"16","key":"2021121006574858400_B53","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.292.16.1969","article-title":"Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial","volume":"292","author":"Pediatric OCD Treatment Study (POTS) Team","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"2021121006574858400_B54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jama.292.7.807","article-title":"Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial","volume":"292","author":"March","year":"2004","journal-title":"JAMA"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/5\/e1312\/908736\/zpe005110e1312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/5\/e1312\/908736\/zpe005110e1312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:06:20Z","timestamp":1741122380000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/127\/5\/e1312\/64940\/A-Systematic-Review-of-Medical-Treatments-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,1]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5,1]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2011-0427","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,1]]}}}